Table 2.
Anti-fracture efficacy of approved treatments for postmenopausal women with osteoporosis when given with calcium and vitamin D
| Intervention | Vertebral fracture | Non-vertebral fracture | Hip fracture |
|---|---|---|---|
| Alendronate | A | A | A |
| Ibandronate | A | A* | NAE |
| Risedronate | A | A | A |
| Zoledronic acid | A | A | A |
| Calcitriol | A | NAE | NAE |
| Denosumab | A | A | A |
| HRT | A | A | A |
| Raloxifene | A | NAE | NAE |
| Teriparatide | A | A | NAE |
A grade A recommendation, NAE not adequately evaluated, HRT hormone replacement therapy
*In subsets of patients only (post hoc analysis)